Evaluation of Anemia Related Factors in Hemodialysis Patients
Renal Anemia in Hemodialysis
Abstract views: 161
/ 
PDF downloads: 73
DOI:
https://doi.org/10.5281/zenodo.13259605Keywords:
Anemia, ferritin, hemodialysis, hemoglobin, mortalityAbstract
Background: To evaluate hemodialysis patients in terms of anemia and mortality-related factors.
Methods: A retrospective evaluation was conducted on ninety-nine hemodialysis patients from Bitlis, Turkey. The analysis involved comparing hemoglobin and ferritin levels and doses of ESA and iron administered. Additionally, mortality-related factors were analyzed.
Results: Patients with lower hemoglobin levels had significantly higher CRP and PTH levels but lower ferritin, total cholesterol, LDL, and glucose levels. The dose of ESA was higher, and the surface area of dialyzers was significantly lower in patients with lower hemoglobin levels. Patients with high ferritin levels had significantly higher CRP, lower hemoglobin levels, and longer dialysis vintage. Patients who received more than 200 mg of intravenous iron per month had significantly higher numbers of patients with diabetic nephropathy, higher CRP, and glucose levels but lower PTH and creatinine levels, lower transferrin saturation, and lymphocyte counts. Patients who received lower doses of ESA had significantly higher LDL, total cholesterol, hemoglobin levels, and higher surface area of dialyzers used but lower ferritin levels. Finally, hemoglobin levels < 9 g/dl and increasing IV iron doses were associated with mortality.
Conclusion: Hyperparathyroidism and inflammation were associated with anemia. Anemia and increasing doses of iron were associated with increased mortality.
References
Macdougall IC, Tomson CR, Steenkamp M, Ansell D. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant. 2010;25(3):914-919. doi:10.1093/ndt/gfp550.
Teles F, Amorim de Albuquerque AL, Freitas Guedes Lins IK, Carvalho Medrado P, Falcão Pedrosa Costa A. Quality of life and depression in haemodialysis patients. Psychol Health Med. 2018;23(9):1069-1078. doi:10.1080/13548506.2018.1469779.
Shi Z, Zhen S, Zhou Y, Taylor AW. Hb level, iron intake and mortality in Chinese adults: a 10-year follow-up study. Br J Nutr. 2017;117(4):572-581. doi:10.1017/S000711451700040X
Anemia in CKD – KDIGO, https://kdigo.org/guidelines/anemia-in-ckd/ (accessed 7 September 2021)
Macdougall IC, Obrador GT. How important is transfusion avoidance in 2013?. Nephrol Dial Transplant. 2013;28(5):1092-1099. doi:10.1093/ndt/gfs575
Malyszko J, Malyszko JS, Mysliwiec M. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation. Ren Fail. 2009;31(7):544-548. doi:10.1080/08860220903082606
Kuragano T, Matsumura O, Matsuda A, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86(4):845-854. doi:10.1038/ki.2014.114
Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070-3080. doi:10.1681/ASN.2005040423
Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013;61(1):44-56. doi:10.1053/j.ajkd.2012.07.014
Nafar M, Samavat S, Khoshdel A, Alipour-Abedi B. Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study. Iran J Kidney Dis. 2017;11(1):56-65.
Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol. 2011;15(6):797-809. doi:10.1007/s10157-011-0502-5.
Tanaka M, Komaba H, Fukagawa M. Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients. Ther Apher Dial. 2018;22(3):242-245. doi:10.1111/1744-9987.12685.
Mpio I, Boumendjel N, Karaaslan H, et al. Hyperparathyroïdie secondaire et anémie. Effets d'un calcimimétique sur le contrôle de l'anémie des hémodialysés chroniques. Étude pilote [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study]. Nephrol Ther. 2011;7(4):229-236. doi:10.1016/j.nephro.2011.01.008.
Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2009;53(5):823-834. doi:10.1053/j.ajkd.2008.12.040.
Małyszko J, Koc-Żórawska E, Levin-Iaina N, et al. New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis. Pol Arch Med Wewn. 2012;122(11):537-542.
Ueda N, Takasawa K. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease. Nutrients. 2018;10(9):1173. Published 2018 Aug 27. doi:10.3390/nu10091173.
Jairam A, Das R, Aggarwal PK, et al. Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy. Indian J Nephrol. 2010;20(3):125-131. doi:10.4103/0971-4065.70840
Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol. 2004;15(6):1623-1632. doi:10.1097/01.asn.0000128009.69594.be.
Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis. 2013;61(6):992-1000. doi:10.1053/j.ajkd.2012.10.02720.
Feldman HI, Santanna J, Guo W, et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol. 2002;13(3):734-744. doi:10.1681/ASN.V133734
Bailie GR, Larkina M, Goodkin DA, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87(1):162-168. doi:10.1038/ki.2014.275
Hougen I, Collister D, Bourrier M, et al. Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2018;13(3):457-467. doi:10.2215/CJN.05390517
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 1970 Günal Bilek, Özgür Can
This work is licensed under a Creative Commons Attribution 4.0 International License.
The journal is licensed under a 